Your browser doesn't support javascript.
loading
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Geurts, Birgit S; Battaglia, Thomas W; van Berge Henegouwen, J Maxime; Zeverijn, Laurien J; de Wit, Gijs F; Hoes, Louisa R; van der Wijngaart, Hanneke; van der Noort, Vincent; Roepman, Paul; de Leng, Wendy W J; Jansen, Anne M L; Opdam, Frans L; de Jonge, Maja J A; Cirkel, Geert A; Labots, Mariette; Hoeben, Ann; Kerver, Emile D; Bins, Adriaan D; Erdkamp, Frans G L; van Rooijen, Johan M; Houtsma, Danny; Hendriks, Mathijs P; de Groot, Jan-Willem B; Verheul, Henk M W; Gelderblom, Hans; Voest, Emile E.
Afiliación
  • Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Battaglia TW; Oncode Institute, Utrecht, the Netherlands.
  • van Berge Henegouwen JM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Zeverijn LJ; Oncode Institute, Utrecht, the Netherlands.
  • de Wit GF; Oncode Institute, Utrecht, the Netherlands.
  • Hoes LR; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
  • van der Wijngaart H; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van der Noort V; Oncode Institute, Utrecht, the Netherlands.
  • Roepman P; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • de Leng WWJ; Oncode Institute, Utrecht, the Netherlands.
  • Jansen AML; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Opdam FL; Oncode Institute, Utrecht, the Netherlands.
  • de Jonge MJA; Oncode Institute, Utrecht, the Netherlands.
  • Cirkel GA; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands.
  • Labots M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hoeben A; Hartwig Medical Foundation, Amsterdam, the Netherlands.
  • Kerver ED; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands.
  • Bins AD; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands.
  • Erdkamp FGL; Department of Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van Rooijen JM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Houtsma D; Department of Medical Oncology, Meander, Amersfoort, the Netherlands.
  • Hendriks MP; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands.
  • de Groot JB; Department of Medical Oncology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Verheul HMW; Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
  • Gelderblom H; Department of Medical Oncology, Amsterdam University Medical Centre, location AUMC, Amsterdam, the Netherlands.
  • Voest EE; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geelen, the Netherlands.
BMC Cancer ; 23(1): 205, 2023 Mar 04.
Article en En | MEDLINE | ID: mdl-36870947
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Inestabilidad de Microsatélites Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Inestabilidad de Microsatélites Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos